
Industry: Biotech

Management:

- Executive Leadership: Dr. Yaw Ansong Jnr, Timothy Adamson

- Scientific Advisory Board: Kagya Amoako, Phd; Saion Sinha, PhD; Matt Rinehart, Phd

Finance:

- Current Investors / Financing to Date: \$31K in grants

- Amount of Financing Sought: 500K

Legal: Murtha Cullina

Executive Summary:

Current confirmatory blood diagnostic tests for sickle cell disease is expensive, time-consuming and require skilled personnel. The same is true for other red cell infections such as Malaria and blood diseases such as blood cancers. The idea is provide a quick and affordable AI Backed diagnostic platform.

Company History:

Yaw is a medical doctor from Ghana and a carrier of the Sickle Cell gene. During his practice as a doctor, he saw the devastating effect sickle cell had on his personal relationships as well as his patients. He saw troubled families struggling to afford a diagnosis. This piqued his interest in finding an affordable and reliable diagnostic solution for sickle cell. During graduate school, I met Tim and we discussed how AI can be applied to diagnosis. After settling on sickle cell KOVA was born.

Market Opportunity / Unmet Need:

There are currently over 200 Million people with the sickle cell gene. The global hemoglobinopathies market is worth close to \$5.3Bn. Current confirmatory diagnostic tools require skilled personnel, which are expensive and difficult to use. The global malaria diagnostics market is poised to reach \$1 Bn.

Products/Services - Launched & Pipeline:

Based on Quantitative Phase Imaging (Wide Field Digital Interferometry). Primary technology licensed from Duke. Provisional patent for other property improvements filed.

Commercial / Technical Milestones:

Currently building version 2 of our product. We are derisking our product by building our own 3d phase imaging unit; after which we will automate our device with the deep learning algorithm we build.

Competition:

There is currently not a single test available to diagnose and monitor health of sickle cell patients. Our test not only provides this but also provides it in a faster, more affordable and easier to use way.

Financial Projections (Unaudited): We project \$150M in yearly global revenues within 3 years of launch

Please indicate primary purpose of Presentation: Investment